With endpoints already met, GSK halts trial into new antibiotic

By Ben Hargreaves

- Last updated on GMT

© Andrew Brookes / Getty Images
© Andrew Brookes / Getty Images

Related tags Antibiotics Gsk Clinical trial gepotidacin

The first oral antibiotic treatment for urinary tract infections in over 20 years appears to be possible, after interim analysis advised for trials to be stopped after endpoints were met.

GSK announced that two Phase III trials evaluating gepotidacin to treat uncomplicated urinary tract infection (uUTI) had been halted early for efficacy. The decision was made following a recommendation by an independent data monitoring committee.

According to the company, the committee had conducted an interim analysis of efficacy and safety data in the 3,000 patients across the trial, which led to their recommendation to stop enrolment into the trials.

The action was taken on two trials, EAGLE-2 and EAGLE-3, that had met their primary efficacy endpoint of combined clinical and microbiological resolution, following treatment at the Test-Of-Cure visit for gepotidacin versus nitrofurantoin in patients with a confirmed uUTI and a uropathogen sensitive to nitrofurantoin.

GSK stated that the review by the committee did not identify any safety concerns for the antibiotic.

The company will begin filing with regulators for gepotidacin in the first half of 2023, with final study visits and data collection expected to take place during the first quarter of 2023. Full results of the trials will be presented during the course of next year.

GSK has been working alongside the US government’s Biomedical Advanced Research and Development Authority (BARDA) to develop the antibiotic. The two organizations have been working together on developing new antibiotics since 2013, with the overall aim to fight antibiotic resistance and bioterrorism.

Gepotidacin itself is a novel, investigational bactericidal, first-in-class triazaacenaphthylene antibiotic. The compound is able to inhibit bacterial DNA replication by binding to two different Type II topoisomerase enzymes.

According to GSK, this delivers activity against most strains of E. coli​ and S. saprophyticus​. In addition, due to the equal and independent binding at both enzymes, mutations in both enzymes are needed to significantly affect gepotidacin susceptibility – making it less likely for resistance to develop.

The success of the trials arrive shortly after GSK broadened its pipeline of antibiotics​ through a $66m (€68m) acquisition of Spero’s late-stage antibiotic for complicated urinary tract infection.

Chris Corsico, SVP, development, GSK, said: “Uncomplicated urinary tract infections are the most common outpatient infection with over half of all women developing a uUTI during their lifetime and more than a quarter of women suffering from recurrent uUTIs. There has been no new class of oral antibiotics for uUTI for over 20 years.”

The need to develop various options against urinary tract infections is rising because there is increasing resistance to current antibiotics used.

Related news

Related products

show more

Drug Solubility and the Need for Speed

Drug Solubility and the Need for Speed

Lonza Small Molecules | 28-Mar-2023 | Technical / White Paper

A growing number of new chemical entities are highly insoluble, leading to problems with bioavailability. Drug manufacturers therefore have to find ways...

Are You Prepared to Meet the New FDA Guidelines?

Are You Prepared to Meet the New FDA Guidelines?

Elligo Health Research® | 23-Mar-2023 | Insight Guide

On April 15, 2022, the U.S. Food and Drug Administration issued a new draft guidance to clinical research sponsors on creating a plan to enroll more participants...

ODM and CDASH in CRF design

ODM and CDASH in CRF design

Formedix | 10-Mar-2023 | Technical / White Paper

The lesser-known Operational Data Model (ODM) standard is often overlooked as it's not required by any regulators. So, why should you be interested...

4 Warning Signs Your Research Site Is in Trouble

4 Warning Signs Your Research Site Is in Trouble

Elligo Health Research® | 10-Mar-2023 | Insight Guide

You want your clinical research practice to be a success for your business and your patients, but how can you tell if it’s in trouble? Read this article...

Related suppliers

Follow us


View more